Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine

A Kuendgen; T Gräf; F Zohren; B Hildebrandt; A Hünerlitürkoglu; N Gattermann; R Haas; G Kobbe

doi:10.1016/j.leukres.2006.06.017

Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine

Leuk Res. 2007 Mar;31(3):407-9. doi: 10.1016/j.leukres.2006.06.017. Epub 2006 Aug 4.

Authors

A Kuendgen¹, T Gräf, F Zohren, B Hildebrandt, A Hünerlitürkoglu, N Gattermann, R Haas, G Kobbe

Affiliation

¹ Department of Hematology, Oncology, Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, D-40225 Düsseldorf, Germany. [email protected]

PMID: 16890286
DOI: 10.1016/j.leukres.2006.06.017

Abstract

For patients with acute myeloid leukemia refractory to intensive chemotherapy prognosis is very poor and treatment options are limited. 5-Azacytidine, a demethylating drug, is effective in the treatment of myelodysplastic syndromes when administered at a low-dose, subcutaneously. We report a case of a patient with AML refractory to induction chemotherapy as well as to two high-dose salvage regimens. The patient achieved CR through monotherapy with low-dose azacytidine.

Publication types

Case Reports

MeSH terms

Acute Disease
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Azacitidine / administration & dosage*
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm*
Fatal Outcome
Female
Follow-Up Studies
Humans
Injections, Subcutaneous
Leukemia, Myeloid / diagnosis*
Leukemia, Myeloid / drug therapy*
Middle Aged
Predictive Value of Tests
Prognosis
Remission Induction

Substances

Azacitidine